{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:38:01Z","timestamp":1785245881893,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejca.2020.10.007","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T19:47:37Z","timestamp":1605728857000},"page":"38-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Maintenance therapy in patients with mycosis fungoides or S\u00e9zary syndrome: A neglected topic"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-6028","authenticated-orcid":false,"given":"Rudolf","family":"Stadler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia J.","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.10.007_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2013update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.10.007_bib2","series-title":"Clinical practice guidelines in oncology (NCCN Guidelines\u00ae): primary cutaneous lymphomas, Version 2.2020","year":"2020"},{"key":"10.1016\/j.ejca.2020.10.007_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.10.007_bib5","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.25577","article-title":"Mycosis fungoides and S\u00e9zary syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2020.10.007_bib6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/bjd.18089","article-title":"Characteristics associated with significantly worse quality of life in mycosis fungoides\/S\u00e9zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study","volume":"182","author":"Molloy","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib7","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.ejca.2007.06.015","article-title":"Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?","volume":"43","author":"Dummer","year":"2007","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.10.007_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jid.2019.08.440","article-title":"Survival in mycosis fungoides and Sezary syndrome: how can we predict outcome?","volume":"140","author":"Scarisbrick","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.semdp.2016.11.002","article-title":"A new molecular paradigm in mycosis fungoides and Sezary syndrome","volume":"34","author":"Elenitoba-Johnson","year":"2017","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ejca.2020.10.007_bib11","doi-asserted-by":"crossref","first-page":"eaar5894","DOI":"10.1126\/scitranslmed.aar5894","article-title":"High-Throughput Sequencing of the T cell Receptor \u03b2 gene identifies aggressive early-stage Mycosis Fungoides","volume":"10","author":"De Masson","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2020.10.007_bib12","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma signi\ufb01cantly increases event-free survival and response duration compared with the standard weekly x4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.10.007_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/COC.0000000000000574","article-title":"Maintenance therapy in metastatic solid tumors: innovative strategy or Simple second-line treatment?","volume":"42","author":"Rowinski","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.007_bib14","first-page":"199","article-title":"Chemotherapy maintenance","volume":"22","author":"Kasi","year":"2016","journal-title":"Canc J"},{"key":"10.1016\/j.ejca.2020.10.007_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Canc J"},{"issue":"Suppl 4","key":"10.1016\/j.ejca.2020.10.007_bib16","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.10.007_bib17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/17512433.2014.944500","article-title":"Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma","volume":"7","author":"Talpur","year":"2014","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.ejca.2020.10.007_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the ef\ufb01cacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjd.12890","article-title":"Nitrogen mustard revisited","volume":"170","author":"Knobler","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/cco.2018.10.01","article-title":"Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment","volume":"8","author":"Jennings","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.007_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11912-018-0678-x","article-title":"Systemic treatment options for advanced-stage mycosis fungoides and S\u00e9zary syndrome","volume":"20","author":"Photiou","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2020.10.007_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2020.10.007_bib25","first-page":"809","article-title":"Low dose interferon-alpha2b combined with PUVA is an effective treatment early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group","volume":"84","author":"Rupoli","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2020.10.007_bib26","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.ejca.2020.10.007_bib27","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1200\/jco.2006.24.18_suppl.7541","article-title":"Prospective, randomized multicentre clinical trial on the use of interferon alfa 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II","volume":"24","author":"Stadler","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.007_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2133.2006.07559.x","article-title":"Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides?","volume":"156","author":"Roberge","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib29","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0190-9622(96)90282-0","article-title":"Combined modality therapy for cutaneous T-cell lymphoma","volume":"34","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mjd.2003.449","article-title":"Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma","volume":"49","author":"Duvic","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74(1)","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib32","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1179\/1607845415Y.0000000002","article-title":"Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory\/relapsed cutaneous T-cell lymphoma","volume":"20","author":"Aviles","year":"2015","journal-title":"Hematology"},{"key":"10.1016\/j.ejca.2020.10.007_bib33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.10.007_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2340\/00015555-1359","article-title":"Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland","volume":"92","author":"V\u00e4kev\u00e4","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2020.10.007_bib35","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1111\/jdv.15661","article-title":"Bexarotene as maintenance treatment after therapies other than skin-directed therapy in advanced-stage mycosis fungoides: a pilot study","volume":"33","author":"Pileri","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2020.10.007_bib36","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/bjc.2013.616","article-title":"Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma","volume":"109","author":"Illidge","year":"2013","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2020.10.007_bib37","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.007_bib38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1684\/ejd.2017.3008","article-title":"A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma \u2013 EORTC 21081 (NCT01098656): results and lessons learned for future trial designs","volume":"27","author":"Bagot","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2020.10.007_bib39","unstructured":"NIH, CinicalTrials.gov: Resminostat for maintenance treatment of patients with advanced stage Mycosis fungoides (MF) or S\u00e9zary syndrome (SS) (RESMAIN)."},{"key":"10.1016\/j.ejca.2020.10.007_bib40","series-title":"Poster presentation at world congress of cutaneous lymphomas","author":"Stadler","year":"2020"},{"key":"10.1016\/j.ejca.2020.10.007_bib41","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12272-015-0571-1","article-title":"Histone deacetylase inhibitors in hematological malignancies and solid tumors","volume":"38","author":"Chun","year":"2015","journal-title":"Arch Pharm Res (Seoul)"},{"key":"10.1016\/j.ejca.2020.10.007_bib42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4155\/fmc.12.6","article-title":"HDAC Inhibitors for the treatment of cutaneous T-cell lymphomas","volume":"4","author":"Rangwalla","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/j.ejca.2020.10.007_bib43","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-13-0735","article-title":"First-in-human, pharmacokinetic and pharmacodynamic phase I study of resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors","volume":"19","author":"Brunetto","year":"2013","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.10.007_bib44","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00280-015-2741-8","article-title":"A phase I study of resminostat in Japanese patients with advanced solid tumors","volume":"75","author":"Kitazono","year":"2015","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2020.10.007_bib45","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.10.007_bib46","doi-asserted-by":"crossref","first-page":"djv225","DOI":"10.1093\/jnci\/djv225","article-title":"Design issues in randomized clinical trials of maintenance therapies","volume":"107","author":"Freidlin","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2020.10.007_bib47","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920310650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920310650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:26Z","timestamp":1760732966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920310650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":47,"alternative-id":["S0959804920310650"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance therapy in patients with mycosis fungoides or S\u00e9zary syndrome: A neglected topic","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}